There has never been a greater time or need than now for pharma to move the needle on making clinical trials more inclusive. The COVID-19 pandemic has highlighted the health disparities experienced by underserved and underrepresented communities. While there are other diversity and inclusion (DEI) conferences, many only dedicate a single track to the topic, and few are specifically focused on DEI in clinical trials.

This event will provide a comprehensive and interactive forum for exchanging ideas and information – with a well-rounded agenda that helps attendees gain a deep understanding of the challenges involved in diverse enrollment in clinical studies, and the ways in which they can make meaningful changes within their organizations. Attendees will walk away with all-new insights and actionable strategies for improving diversity in clinical trials.

DGE is proud to invite you and your colleagues to attend the 3rd Diversity in Clinical Trials Summit-the most in-depth conference available for:

  • Participating in a group process that will gain full understanding of the FDA’s action plans and FDORA
  • Understanding the problems of DCT in the past, current efforts to overcome these issues and raise the bar for future goals and achievements
  • Gain insight into the fact that DCT is one of the most important areas for the life sciences industry to address in order to best serve patients and develop the most effective treatments
  • Prepare for the Future, discuss opportunities for improvement and identify key resources for future development while establishing boundaries to avoid repeating history

Share this conference

Related Content

Keeping pace with the evolving global landscape in vaccine development

Keeping pace with the evolving global landscape in vaccine development

Hear from a panel of Life Science experts on the latest advancements and innovative modalities paving the way in the global vaccine development space. What has been COVID-19's impact on drug development and the regulatory landscape? Key factors contributing to Asia Pacific being recognised as the hub for vaccine development and opportunities for biotech's to leverage. Key considerations for pre-clinical and clinical planning to accelerate vaccine development, supporting a robust global strategy.